Posted by Michael Wonder on 03 Jan 2018
Trevena announces FDA acceptance for review of new drug application for Olinvo (oliceridine) injection
2 January 2018 - Trevena today announced that the U.S. FDA has accepted the company’s new drug application for Olinvo (oliceridine) injection.
The company expects that the PDUFA date for the application will be in the fourth quarter of 2018.
Olinvo is an investigational product for the management of moderate to severe acute pain. It is the first G protein biased ligand of the mu receptor designed to provide IV opioid pain relief with fewer associated adverse effects.
